Health Reading List | June 26, 2015 |
Hello hello,
SCOTUS finally handed down the much anticipated King vs. Burwell ruling, and no surprises: the challenge was rejected. There are a few analyses this week on what that means for insurance companies (the real winners) and health entrepreneurs.
Have a great one,
Scott
Startup Highlight: CRISPR Therapeutics
CRISPR has been around for some time, and now a few startups are popping up around the world altering technique. CRISPR Therapeutics is one of them.
"CRISPR Therapeutics is a biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough genome-editing technology, into transformative medicines for serious human diseases. We are uniquely positioned to translate CRISPR-Cas9 technology into human therapeutics, thanks to our multi-disciplinary team of world-renowned academics, clinicians and drug developers. CRISPR Therapeutics' vision is to cure serious human diseases at the molecular level using CRISPR-Cas9."
As always, if you come across news, announcements, videos, or podcasts that you think everyone else would benefit from, e-mail me at scott.munro@startupdigestmail.com or tweet @R_Scott_Munro. | Hiring? Access 250+ new candidates every Monday.  Great companies are built with great teams. With Hired, access over 250 pre-screened developers, designers, and tech sales professionals every week all ready to explore new opportunities. Use Hired to find the best talent in tech so you can focus on what you do best. Sign up and make the key hires you need. | | Leah Libresco - Five Thirty Eight "That rise amounted to a $3 billion increase in the combined market capitalization of the five companies. And that figure underestimates the decision's real benefit to these companies. According to FantasySCOTUS, a prediction market that has been fairly successful at forecasting the outcome of Supreme Court decisions, the government was favored to prevail in its case. Assuming investors were similarly optimistic about the government's chances, the pre-decision stock prices likely reflected the predicted outcome, meaning the bounce started from higher up than it might have otherwise." | | Unity Stokes - Forbes Rather than focusing on the uninsured or the insurance companies themselves, Unity Stokes focuses on the disruption in the industry that the ACA has caused, and the opportunity that exists (and will continue to exist) because of the legislation. | | PwC PwC has a great update to its ongoing ACA coverage with many many juicy stats. A good primer to review the current and far-reaching implications of the ACA implementation. | | Liz Stinson - Wired "Called Organs-On-Chips, it's exactly what it sounds like: A microchip embedded with hollow microfluidic tubes that are lined with human cells, through which air, nutrients, blood and infection-causing bacteria could be pumped. These chips get manufactured the same way companies like Intel make the brains of a computer. But instead of moving electrons through silicon, these chips push minute quantities of chemicals past cells from lungs, intestines, livers, kidneys and hearts." | | Jennifer Doudna, PhD - Medium Jennifer Doudna is awesome, and CRISPR is the stuff of Sci-Fi. So why not read an article written by her on the topic? | | Michael J. Joyner, MD, Nigel Paneth, MD, MPH - JAMA Precision Medicine has some great promise, but many questions remain on it's impact (both financial and otherwise). JAMA has a great overview here. | | Aaron Stanley - Financial Times FT's article on innovation in healthcare is a good complement to Unity Stokes' piece, and a definite must read. | | | You are receiving this email because you believe that the best startup articles and videos are made by active members of the startup community. © 2009-2015 Startup Digest. Startup Digest is a registered trademark of Startup Weekend. Privacy Policy. All rights reserved. | | |
